|
|
Post by orlon on Nov 16, 2015 11:13:59 GMT -5
A new lawsuit against Sanofi was filed today for stalling the development of an MS drug by Genzyme, failing to keep their promise to promote the drug after approval by the FDA...a second attempt, the first submission hindered by SNY....and pushing their own MS drug instead of the better one developed by Genzyme. Genzyme's treatment by Sanofi is remarkably similar to Mannkind's. The story about the lawsuit was on Reuters this morning.
|
|
|
|
Post by doodyfree on Nov 16, 2015 11:17:15 GMT -5
old news
|
|
|
|
Post by wmdhunt on Nov 16, 2015 11:29:01 GMT -5
How can it be "old news" if it was filed today?
|
|
|
|
Post by suebeeee1 on Nov 16, 2015 11:31:31 GMT -5
|
|
|
|
Post by cathode on Nov 16, 2015 11:38:55 GMT -5
|
|
|
|
Post by EveningOfTheDay on Nov 20, 2015 18:28:29 GMT -5
No one posted this today, [Edit: Falcon beat me to it while I was composing away] so I thought it should be put out here- it is not new, but it is another story that makes one question whether Sanofi can really do the right job. www.cnbc.com/2015/11/20/sanofi-whistleblower-lawsuit-kicks-into-higher-gear.html?__source=yahoo|finance|headline|headline|story&par=yahoo&doc=103179002Does this effectively tie their hands from aggressively marketing Afrezza, which we so sorely need? That leads me to my next thought, when we find whether the clamp study generated anything that can be used to enhance the label (as has been speculated on this board). Given this environment, I think SNY management may keep efforts close to the legal limits, but who knows. They apparently have played dirty in the past. Seems unreasonable to think that Sanofi was looking for a silver bullet to all its problems, which at the same time would require no gun to be shot with. I, like you, wonder about the studies that necessarily must have been conducted in the last 10 months and the results. For all we know Afrezza works very well, but seeing how much we are not being told, I have to wonder if there is some ulterior reason for which we are not being told, other than the overused competitive reasons. This is the problem when you are neither forthcoming, not straightforward in your communications, constant speculation makes for extreme volatility and I can not believe that Mat or Al or any other person with a minimum understanding of the markets would see it any other way. One has to wonder if they are allowing all this because they simply have no option. I used to think there was some type of plan behind it, but it is becoming painfully obvious that possibly there is none. Anyway, hopefully JoeyP&P will wage in at some point with some insight from the Sanofi rep he has befriended. His, and a few others, are some of the very few posts I still look forward to read. |
|
